Heron Therapeutics, Inc. HRTX

HRTX Company Overview

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapeutics that address unmet needs in pain management and oncology supportive care. The company operates primarily within the biopharmaceutical industry, with an emphasis on acute care and post-surgical recovery products. Heron’s revenue is primarily derived from sales of FDA-approved products used in hospital, ambulatory surgery center, and oncology treatment settings.

Heron’s core commercial portfolio includes ZYNRELEF, an extended-release local anesthetic for post-operative pain management; CINVANTI and SUSTOL, which are used to prevent chemotherapy-induced nausea and vomiting; and APONVIE, an injectable antiemetic therapy. The company has positioned itself around differentiated drug-delivery technologies intended to improve efficacy, reduce opioid use, and simplify treatment protocols. Founded in 1983 and formerly known as A.P. Pharma, Inc., the company adopted the Heron Therapeutics name in 2013 as it expanded beyond its original oncology-supportive-care focus into acute pain therapeutics.